Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Forum for Health Economics & Policy

Editor-in-Chief: Goldman, Dana


CiteScore 2017: 0.53

SCImago Journal Rank (SJR) 2017: 0.425
Source Normalized Impact per Paper (SNIP) 2017: 0.297

Online
ISSN
1558-9544
See all formats and pricing
More options …

Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants

Seth A. Seabury
  • Corresponding author
  • Associate Professor of Research, Department of Emergency Medicine and the Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, USC Schaeffer Center, 635 Downey Way, VPD Suite 210, Los Angeles, CA 90089-3333, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Darius N. Lakdawalla / Deborah Walter / John Hayes / Thomas Gustafson / Anshu Shrestha / Dana P. Goldman
Published Online: 2014-11-07 | DOI: https://doi.org/10.1515/fhep-2014-0016

Abstract

Many state Medicaid programs have implemented policies designed to reduce spending on prescription drugs by restricting access to branded products. For patients with major depressive disorder, formulary restrictions could severely limit access to antidepressant therapies and disrupt care. We linked data on patient outcomes and spending from 24 state Medicaid programs to information on formulary restrictions from 2001 to 2008. Outcomes included frequency of MDD-related hospitalizations and ER visits per patient and total healthcare spending. We estimated the effect of the policies on patient outcomes and spending using a difference-and-difference approach. We found that restricting access to antidepressants increased the probability of an MDD-related hospitalization by 1.7 percentage points (16.6%). Furthermore, we found no evidence that these restrictions resulted in any net savings for Medicaid.

Keywords: depression; Medicaid; prescription drug coverage

References

  • Adelmann, P. K. (2003) “Mental and Substance Use Disorders Among Medicaid Recipients: Prevalence Estimates from Two National Surveys,” Administration and Policy in Mental Health, 31:111–129.CrossrefGoogle Scholar

  • Amador, X. F., J. H. Friedman, C. Kasapis, et al. (1996) “Suicidal Behavior in Schizophrenia and its Relationship to Awareness of Illness.” The American Journal of Psychiatry, 153:1185–1188.Google Scholar

  • Angrist, J. D. and A. B. Krueger (1999) “Empirical Strategies in Labor Economics,” Handbook of Labor Economics, 3:1277–1366.Google Scholar

  • Association, A. P. (1993) “Practice Guideline for Major Depressive Disorder in Adults,” Amer Psychiatric Pub Incorporated.Google Scholar

  • Association, A. P. (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR®. American Psychiatric Pub.Google Scholar

  • Chen, Y., C. M. Kelton, Y. Jing, et al. (2008) “Utilization, Price, and Spending Trends for Antidepressants in the US Medicaid Program,” Research in Social & Administrative Pharmacy: RSAP, 4:244–257.CrossrefWeb of ScienceGoogle Scholar

  • Farley, J. F., R. R. Cline, J. C. Schommer, et al. (2008) “Retrospective Assessment of Medicaid Step-therapy Prior Authorization Policy for Atypical Antipsychotic Medications,” Clinical Therapeutics, 30:1524–1539; discussion 1506–1527.Web of ScienceCrossrefGoogle Scholar

  • Goldman, D. P., G. F. Joyce and P. Karaca-Mandic (2006) “Varying Pharmacy Benefits with Clinical Status: The Case of Cholesterol-lowering Therapy,” American Journal of Managed Care, 12:21–28.Google Scholar

  • Goldman, D.P., R. Dirani, J. Fastenau and R. M. Conrad (2014a) “Do Strict Formularies Replicate Failure for Patients With Schizophrenia?,” American Journal of Managed Care, 20:219–228.Google Scholar

  • Goldman, D., J. Fastenau, R. Dirani, E. Helland, G. Joyce, R. Conrad and D. Lakdawalla (2014b) “Medicaid Prior Authorization Policies and Imprisonment Among Patients With Schizophrenia,” American Journal of Managed Care, 20:577–586.Google Scholar

  • Institute for Clinical Systems Improvement (2008) Major Depression in Adults in Primary Care.Google Scholar

  • Joyce, G. F., D. P. Goldman, P. Karaca-Mandic, et al. (2008) “Impact of Specialty Drugs on the Use of Other Medical Services,” The American Journal of Managed Care, 14:821–828.Google Scholar

  • Karaca-Mandic, P., A. B. Jena, G. F. Joyce, et al. (2012) “Out-of-pocket Medication Costs and Use of Medications and Health Care Services Among Children with Asthma,” Journal of the American Medical Association, 307:1284–1291.Google Scholar

  • Koyanagi, C., S. Forquer and E. Alfano (2005) “Medicaid Policies to Contain Psychiatric Drug Costs,” Health Affairs (Project Hope), 24:536–544.CrossrefGoogle Scholar

  • Law, M., D. Ross-Degnan and S. Soumerai (2008) “Effect of Prior Authorization of Second-generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements,” Psychiatric Services, 59:540–546.CrossrefWeb of ScienceGoogle Scholar

  • MedPAC (2011) A Data Book: Health Care Spending and the Medicare Program.Google Scholar

  • Raebel, M. A., J. Schmittdiel, A. J. Karter, J. L. Konieczny and J. F. Steiner (2013) “Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases,” Medical Care, 51:S11-S21.PubMedWeb of ScienceCrossrefGoogle Scholar

  • Sicras-Mainar, A., J. Maurino, L. Cordero, et al. (2012) “Assessment of Pharmacological Strategies for Management of Major Depressive Disorder and their Costs after an Inadequate Response to First-line Antidepressant Treatment in Primary care,” Annals of General Psychiatry, 11:22.Web of ScienceGoogle Scholar

  • Soumerai, S. B., T. J. McLaughlin, D. Ross-Degnan, et al. (1994) “Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia,” New England Journal of Medicine, 331:650–655.Google Scholar

  • Soumerai, S. B., F. Zhang, D. Ross-Degnan, et al. (2008) “Use of Atypical Antipsychotic Drugs for Schizophrenia in Maine Medicaid Following a Policy Change,” Health Affairs, 27:w185–w195.CrossrefWeb of ScienceGoogle Scholar

  • Vogt, W. B., G. Joyce, J. Xia, et al. (2011) “Medicaid Cost Control Measures Aimed at Second-generation Antipsychotics Led to Less Use of All Antipsychotics,” Health Affairs (Project Hope), 30:2346–2354.CrossrefWeb of ScienceGoogle Scholar

  • Zhang, Y., A. Adams, D. Ross-Degnan, et al. (2009) “Effects of Prior Authorization on Medication Discontinuation Among Medicaid Beneficiaries with Bipolar Disorder,” Psychiatric Services, 60:520–527.Google Scholar

About the article

Corresponding author: Seth A. Seabury, PhD, Associate Professor of Research, Department of Emergency Medicine and the Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, USC Schaeffer Center, 635 Downey Way, VPD Suite 210, Los Angeles, CA 90089-3333, USA, Phone: +310-623-2025, e-mail:


Published Online: 2014-11-07

Published in Print: 2014-09-01


Citation Information: Forum for Health Economics and Policy, Volume 17, Issue 2, Pages 153–168, ISSN (Online) 1558-9544, ISSN (Print) 2194-6191, DOI: https://doi.org/10.1515/fhep-2014-0016.

Export Citation

©2014 by De Gruyter.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Diane S Rohlman, Shelly Campo, Jennifer Hall, Erin L Robinson, and Kevin M Kelly
Annals of Work Exposures and Health, 2018, Volume 62, Number suppl_1, Page S34

Comments (0)

Please log in or register to comment.
Log in